Literature DB >> 24630929

Adenanthin targets proteins involved in the regulation of disulphide bonds.

Angelika Muchowicz1, Małgorzata Firczuk1, Justyna Chlebowska1, Dominika Nowis2, Joanna Stachura1, Joanna Barankiewicz1, Anna Trzeciecka1, Szymon Kłossowski3, Ryszard Ostaszewski3, Radosław Zagożdżon1, Jian-Xin Pu4, Han-Dong Sun5, Jakub Golab6.   

Abstract

Adenanthin has been recently shown to inhibit the enzymatic activities of peroxiredoxins (Prdx) I and II through its functional α,β-unsaturated ketone group serving as a Michael acceptor. A similar group is found in SK053, a compound recently developed by our group to target the thioredoxin-thioredoxin reductase (Trx-TrxR) system. This work provides evidence that next to Prdx I and II adenanthin targets additional proteins including thioredoxin-thioredoxin reductase system as well as protein disulfide isomerase (PDI) that contain a characteristic structural motif, referred to as a thioredoxin fold. Adenanthin inhibits the activity of Trx-TR system and PDI in vitro in the insulin reduction assay and decreases the activity of Trx in cultured cells. Moreover, we identified Trx-1 as an adenanthin binding protein in cells incubated with biotinylated adenanthin as an affinity probe. The results of our studies indicate that adenanthin is a mechanism-selective, rather than an enzyme-specific inhibitor of enzymes containing readily accessible, nucleophilic cysteines. This observation might be of importance in considering potential therapeutic applications of adenanthin to include a range of diseases, where aberrant activity of Prdx, Trx-TrxR and PDI is involved in their pathogenesis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenanthin; Cancer; Peroxiredoxin; Protein disulphide isomerase; Thioredoxin

Mesh:

Substances:

Year:  2014        PMID: 24630929     DOI: 10.1016/j.bcp.2014.02.022

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Trapping redox partnerships in oxidant-sensitive proteins with a small, thiol-reactive cross-linker.

Authors:  Kristin M Allan; Matthew A Loberg; Juliet Chepngeno; Jennifer E Hurtig; Susmit Tripathi; Min Goo Kang; Jonathan K Allotey; Afton H Widdershins; Jennifer M Pilat; Herbert J Sizek; Wesley J Murphy; Matthew R Naticchia; Joseph B David; Kevin A Morano; James D West
Journal:  Free Radic Biol Med       Date:  2016-11-02       Impact factor: 7.376

2.  Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells.

Authors:  Marta Siernicka; Magdalena Winiarska; Malgorzata Bajor; Malgorzata Firczuk; Angelika Muchowicz; Malgorzata Bobrowicz; Cyril Fauriat; Jakub Golab; Daniel Olive; Radoslaw Zagozdzon
Journal:  Immunology       Date:  2015-07-08       Impact factor: 7.397

Review 3.  Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease.

Authors:  Robert Flaumenhaft; Bruce Furie; Jeffrey I Zwicker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-07       Impact factor: 8.311

4.  Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells.

Authors:  J-K Hou; Y Huang; W He; Z-W Yan; L Fan; M-H Liu; W-L Xiao; H-D Sun; G-Q Chen
Journal:  Cell Death Dis       Date:  2014-09-04       Impact factor: 8.469

Review 5.  New insights into redox homeostasis as a therapeutic target in B-cell malignancies.

Authors:  Agnieszka Graczyk-Jarzynka; Radoslaw Zagozdzon; Angelika Muchowicz; Marta Siernicka; Przemyslaw Juszczynski; Malgorzata Firczuk
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

6.  Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia.

Authors:  Klaudyna Fidyt; Agata Pastorczak; Agnieszka Goral; Kacper Szczygiel; Wojciech Fendler; Angelika Muchowicz; Marcin Adam Bartlomiejczyk; Joanna Madzio; Julia Cyran; Agnieszka Graczyk-Jarzynka; Eugene Jansen; Elzbieta Patkowska; Ewa Lech-Maranda; Deepali Pal; Helen Blair; Anna Burdzinska; Piotr Pedzisz; Eliza Glodkowska-Mrowka; Urszula Demkow; Karolina Gawle-Krawczyk; Michal Matysiak; Magdalena Winiarska; Przemyslaw Juszczynski; Wojciech Mlynarski; Olaf Heidenreich; Jakub Golab; Malgorzata Firczuk
Journal:  Mol Oncol       Date:  2019-04-05       Impact factor: 6.603

7.  Validation of Cadherin HAV6 Peptide in the Transient Modulation of the Blood-Brain Barrier for the Treatment of Brain Tumors.

Authors:  Babu V Sajesh; Ngoc H On; Refaat Omar; Samaa Alrushaid; Brian M Kopec; Wei-Guang Wang; Han-Dong Sun; Ryan Lillico; Ted M Lakowski; Teruna J Siahaan; Neal M Davies; Pema-Tenzin Puno; Magimairajan Issai Vanan; Donald W Miller
Journal:  Pharmaceutics       Date:  2019-09-17       Impact factor: 6.321

8.  Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma.

Authors:  Anna Trzeciecka; Szymon Klossowski; Malgorzata Bajor; Radoslaw Zagozdzon; Pawel Gaj; Angelika Muchowicz; Agata Malinowska; Anna Czerwoniec; Joanna Barankiewicz; Antoni Domagala; Justyna Chlebowska; Monika Prochorec-Sobieszek; Magdalena Winiarska; Ryszard Ostaszewski; Iwonna Gwizdalska; Jakub Golab; Dominika Nowis; Malgorzata Firczuk
Journal:  Oncotarget       Date:  2016-01-12

Review 9.  Oxidative Stress in Kidney Diseases: The Cause or the Consequence?

Authors:  Natalia Krata; Radosław Zagożdżon; Bartosz Foroncewicz; Krzysztof Mucha
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-12-06       Impact factor: 4.291

10.  Peroxiredoxin-1 Overexpression Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Oxidative Stress and Cardiomyocyte Apoptosis.

Authors:  Lai Jiang; Yanping Gong; Yida Hu; Yangyang You; Jiawu Wang; Zhetao Zhang; Zeyuan Wei; Chaoliang Tang
Journal:  Oxid Med Cell Longev       Date:  2020-07-29       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.